NGNE
Neurogene Inc

349
Mkt Cap
$292.76M
Volume
21,841.00
52W High
$37.27
52W Low
$6.88
PE Ratio
-4.27
NGNE Fundamentals
Price
$19.85
Prev Close
$18.90
Open
$19.40
50D MA
$18.70
Beta
1.47
Avg. Volume
145,561.05
EPS (Annual)
-$4.28
P/B
1.05
Rev/Employee
$8,644.86
$101.61
Loading...
Loading...
News
all
press releases
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit
Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company...
Business Wire·20d ago
News Placeholder
Neurogene (NASDAQ:NGNE) Now Covered by Analysts at Lifesci Capital
Lifesci Capital initiated coverage on shares of Neurogene in a research note on Monday. They issued an "outperform" rating and a $50.00 price target for the company...
MarketBeat·1mo ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Analysts
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has received a consensus rating of "Hold" from the seven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst...
MarketBeat·1mo ago
News Placeholder
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on...
Business Wire·1mo ago
News Placeholder
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company...
Business Wire·2mo ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Brokerages
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been given an average rating of "Hold" by the seven ratings firms that are currently covering the company, MarketBeat.com reports. One...
MarketBeat·2mo ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of "Hold" from Brokerages
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has received an average recommendation of "Hold" from the seven brokerages that are covering the company, MarketBeat.com reports. One analyst has rated...
MarketBeat·2mo ago
News Placeholder
Neurogene (NASDAQ:NGNE) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Neurogene from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Hold" by Brokerages
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned an average recommendation of "Hold" from the seven analysts that are covering the firm, MarketBeat Ratings reports. One...
MarketBeat·3mo ago
<
1
2
...
>

Latest NGNE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.